Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

spearnreel Jul. 16 at 12:11 PM

$BSX Med tech showing life today off heels of $ABT reporting. $JNJ forecasting to hit $100 bil annual revs 2026, first in history. Frothy tech and specs showing weakness and should lead to reallocation here imo. Analysts completed their tasks in beating down the sector with constant PT revisions all the while maintaining buy recommendations. This is typically the recipe for real reversal and we can star in this show starting today if we want it. $MDT $ISRG

0 · Reply

SellasgpsCurativeBAT11 Jul. 16 at 11:58 AM

$SLS $JNJ JNJ said it aims to become the world's No. 1 oncology company by 2030 with over $50 billion in sales. Big Pharma's next oncology target after Johnson & Johnson doubled down on acquisitions and its goal of becoming the world's No. 1 cancer-drug company. $SLS Next up. $SLS BOD Katherine Bach that bought shares on open market twice last year was also a Johnson & Johnson VP of Franchise Strategic Management for 10 years. She then worked atCelgene as a VP of Corporate Strategy for 5 years before Bristol-Myers acquired them for $74B. ✌️🙏❤️‍🩹

0 · Reply

outlawinvestor1 Jul. 16 at 11:12 AM

$ATAI $JNJ $HELP $CMPS

0 · Reply

Petersen73 Jul. 16 at 8:09 AM

$IBRX $JNJ $SLS

0 · Reply

WolfOfWillowick Jul. 16 at 8:01 AM

$IBRX $JNJ $SLS

0 · Reply

StocktwitsNews Jul. 16 at 7:12 AM

SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot $SLS $IBRX $JNJ https://stocktwits.com/news/equity/markets/sls-ibrx-retail-big-pharma-buyouts-jnj-no1-oncology-spot/cZZEcThR7rH

0 · Reply

leLu83 Jul. 16 at 1:03 AM

$ATAI we just bat signaled the entire pharma sector 💯 Johnson & Johnson ($JNJ) is the biggest wildcard in this scenario. Their blockbuster psychiatric drug Spravato (esketamine) is currently pacing toward multi-billion-dollar annual revenues. The Threat: BPL-003 represents a massive, direct threat to Spravato because it boasts a 90-minute in-clinic monitoring window compared to Spravato's rigid 2-hour requirement. The Action: J&J has a massive balance sheet and a strong defensive incentive to overbid Eli Lilly to keep BPL-003 out of a competitor's hands—or to capture the next-generation market leader themselves.

2 · Reply

leLu83 Jul. 16 at 12:58 AM

$ATAI JnJ should really make an offer bc Lilly will completely destroy spravato soon in clinics. They have cash. They should moat their leading growth blockbuster drug. Lilly looking to dominate short acting CNS psychs. JnJ going to let it slip? $JNJ

0 · Reply

Millionaire11 Jul. 16 at 12:36 AM

$CMPS this has became real very fast $JNJ and others are going to want to jump in quick or $LLY is going to be only of the few big pharma companies with access to this new class of mental health drugs.

1 · Reply

Millionaire11 Jul. 15 at 10:59 PM

$CMPS - $ATAI buy out from $LLY that means $JNJ could still be eying $CMPS. Lets hope for a massive buy out price of 10 billion plus. That would be massive for the whole industry. Good luck every body and trust the process.

1 · Reply

Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs

2026-07-16T11:30:25.000Z - 42 minutes ago

Johnson & Johnson price target raised to $270 from $260 at JPMorgan

2026-07-16T10:50:21.000Z - 1 hour ago

Johnson & Johnson price target raised to $294 from $284 at Morgan Stanley

2026-07-16T10:15:25.000Z - 1 hour ago

Johnson & Johnson price target raised to $272 from $263 at Wells Fargo

2026-07-15T19:30:21.000Z - 16 hours ago

Johnson & Johnson price target raised to $260 from $250 at Stifel

Jul 15, 2026, 12:09 PM EDT - 20 hours ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

2026-07-15T13:26:33.000Z - 22 hours ago

Johnson & Johnson: Expiration of ACA subsidies won’t impact procedure demand

2026-07-15T13:18:06.000Z - 22 hours ago

Johnson & Johnson Stock (JNJ) Falls despite Q2 Beat, Higher Sales Forecast for 2026

2026-07-15T13:15:12.000Z - 22 hours ago

Johnson & Johnson says three of four business units accelerated through Q2

2026-07-15T13:11:16.000Z - 23 hours ago

Johnson & Johnson expects operational sales growth to improve in 2H26

2026-07-15T13:00:31.000Z - 23 hours ago

Johnson & Johnson says capital allocation priorities remain unchanged

2026-07-15T12:55:17.000Z - 23 hours ago

Johnson & Johnson says confident in long term projections of Medtech business

2026-07-15T12:45:21.000Z - 23 hours ago

Johnson & Johnson says has strongest portfolio, pipeline in company’s history

Jul 15, 2026, 8:30 AM EDT - 23 hours ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 23 hours ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 23 hours ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 1 day ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 1 day ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 1 day ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

2026-07-15T10:26:19.000Z - 1 day ago

Johnson & Johnson reports Q2 adjusted EPS $2.90, consensus $2.85

2026-07-15T10:25:32.000Z - 1 day ago

Johnson & Johnson raises FY26 adjusted EPS view to $11.60-$11.75

Jul 15, 2026, 6:25 AM EDT - 1 day ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 1 day ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 1 day ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

2026-07-14T17:43:17.000Z - 1 day ago

Polymarket Odds: Will UAL, JNJ, MS Beat Earnings Tomorrow?

MS UAL

2026-07-14T10:49:26.000Z - 2 days ago

Johnson & Johnson Reports Q2 Earnings Tomorrow. What Investors Should Expect.

2026-07-13T13:15:14.000Z - 2 days ago

Johnson & Johnson price target raised to $287 from $265 at RBC Capital

2026-07-13T13:10:33.000Z - 2 days ago

Johnson & Johnson price target raised to $300 from $250 at TD Cowen

Jul 9, 2026, 1:00 PM EDT - 6 days ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 8 days ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 9 days ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 19 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 19 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 21 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 4 weeks ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 4 weeks ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 4 weeks ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 5 weeks ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 5 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

Jun 11, 2026, 2:03 AM EDT - 5 weeks ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 5 weeks ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 5 weeks ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 5 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 5 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 8:08 AM EDT - 5 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 5 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 3, 2026, 12:04 AM EDT - 6 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 6 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

spearnreel Jul. 16 at 12:11 PM

0 · Reply

SellasgpsCurativeBAT11 Jul. 16 at 11:58 AM

0 · Reply

outlawinvestor1 Jul. 16 at 11:12 AM

$ATAI $JNJ $HELP $CMPS

0 · Reply

Petersen73 Jul. 16 at 8:09 AM

$IBRX $JNJ $SLS

0 · Reply

WolfOfWillowick Jul. 16 at 8:01 AM

$IBRX $JNJ $SLS

0 · Reply

StocktwitsNews Jul. 16 at 7:12 AM

0 · Reply

leLu83 Jul. 16 at 1:03 AM

2 · Reply

leLu83 Jul. 16 at 12:58 AM

0 · Reply

Millionaire11 Jul. 16 at 12:36 AM

1 · Reply

Millionaire11 Jul. 15 at 10:59 PM

1 · Reply

MichaelNaussCMT Jul. 15 at 9:02 PM

$ATAI $CMPS $DFTX $HELP $JNJ price action tells you this a long time ago

0 · Reply

Bazziggr Jul. 15 at 8:57 PM

$JNJ BSX

0 · Reply

UltimateTrader_22 Jul. 15 at 6:51 PM

$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI

0 · Reply

Jack90 Jul. 15 at 6:47 PM

Loading $PFE, $BMY, $JNJ

0 · Reply

musicalchairsponzi Jul. 15 at 6:25 PM

$JNJ is this an AI company? Why is it up like 80% in the last year lol

1 · Reply

khalidsa Jul. 15 at 5:51 PM

$JNJ I hope to enter the baby diaper manufacturing business soon; maybe things will improve a little. 🥸

0 · Reply

BarkingPuppy Jul. 15 at 5:25 PM

$JNJ

1 · Reply

theoptionsplug Jul. 15 at 5:17 PM

$JNJ testing its previous resistance area as support! Earning report shows a raise for its full-year guidance after reporting second-quarter adjusted earnings of $2.90 a share! The company’s quarterly sales rise 6% from the same period last year to $25 billion Respected $250 will set up a BEAUTIFUL move!

0 · Reply

BarkingPuppy Jul. 15 at 5:04 PM

$DJT $JNJ $PFE $MRNA $LLY Let me share a little secret with you..... This is why ELTP is going to be Big..... Their Technology will save the world... Look it up/ Here are the two people who are backing ELTP.

1 · Reply

Suite510 Jul. 15 at 5:01 PM

$JNJ $KVUE JNJ shares fall too, med tech earnings miss and huge Talc and Tylenol legal risks, that’s perfect medicine for them 🤣🙈

1 · Reply

DidYouReadThis Jul. 15 at 4:36 PM

$OTLK 2 weeks before 7/29/26 #PDUFA… Bottom Bollinger looks like 1.40? How many more more super sales, can it drop under 1.40, with a little help from some stop losses, or shorts? #stillLONG $REGN $PFE $JNJ

0 · Reply

parcha Jul. 15 at 4:21 PM

Jim Cramer's top 10 things to watch in the stock market Wednesday $JNJ $XLV Club name Johnson & Johnson delivered a beat-and-raise this morning, though the stock is down 2%. Tremfya, one of its key growth drugs, topped expectations. There was some weakness on the medical-device side, specifically within cardiology. Not ideal, but I am confident they can fix the problem. Could be a chance to buy once the dust settles on the quarter. https://www.cnbc.com/2026/07/15/jim-cramers-top-10-things-to-watch-in-the-stock-market-wednesday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

0 · Reply

Market Cap	611.07B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.02
Forward PE	22.26
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	10,547,200
Avg Vol	8,216,500
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	4%
Beta	0.24
Analysts	Strong Sell
Price Target	$265.44